What You Need To Know Ahead of Eli Lilly's Earnings Report Tuesday

Analyst Estimates for Q1 2024Q4 2023Q1 2023Revenue$8.79 billion$9.35 billion$6.96 billionDiluted EPS$2.39$2.42$1.49Net Income$2.15 billion$2.19 billion$1.34 billion Key Metric: New Products Revenue The weight-loss drugs were the biggest driver of Eli Lilly's revenue in the fourth quarter, with Mounjaro accounting for $2.21 billion, with Zepbound generating just $175.8 million in its first quarter on the market. Combined, the two weight-loss drugs made up just over a quarter of Eli Lilly's total fourth qu ...